Home > Insider Trading > Filing (0000899243-20-018253)

Filing Details

Accession Number:: 0000899243-20-018253
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-02 16:02:07
Reporting Period:: 2020-06-30

Accepted Time:: 2020-07-02 16:02:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1805890	Fusion Pharmaceuticals Inc.	FUSN	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	No	No
1157524	Orbimed Capital Llc	601 Lexington Ave, 54Th Floor New York NY 10022	Yes	No	No	No
1760648	Orbimed Capital Gp Vii Llc	501 Lexington Ave, 54Th Floor New York NY 10022	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2020-06-30	2,224,770	$0.00	2,224,770	No	4	C	Indirect	By OrbiMed Private Investments VII, L.P.
Common Shares	Acquisiton	2020-06-30	705,900	$17.00	2,930,670	No	4	P	Indirect	By OrbiMed Private Investments VII, L.P.
Common Shares	Acquisiton	2020-06-30	192,100	$17.00	192,100	No	4	P	Indirect	By OrbiMed Partners Master Fund Limited

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By OrbiMed Private Investments VII, L.P.
No	4	P	Indirect	By OrbiMed Private Investments VII, L.P.
No	4	P	Indirect	By OrbiMed Partners Master Fund Limited

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Class B Preferred Shares	Disposition	2020-06-30	11,878,051	$0.00	2,224,770	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The Class B Preferred Shares were convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, all Class B Preferred Shares converted into Common Shares.
OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Capital LLC ("OrbiMed Capital") is a relying advisor of OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VII.
This report on Form 4 is jointly filed by GP VII, OrbiMed Capital, and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
OrbiMed Capital is the investment advisor to OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPM.